Evolving New Treatment for Myelodysplastic Syndromes
Progress in Hematology
Received: 15 February 2007 Accepted: 29 August 2007 DOI:
10.1532/IJH97.07026 Cite this article as: Yoshida, Y. Int J Hematol (2007) 86: 297. doi:10.1532/IJH97.07026 Abstract
Over the last several years, there has been substantial progress in the definition, diagnosis, and management of myelodysplastic syndromes (MDSs). This progress includes the new World Health Organization classification and the revised standardized response criteria to be applicable to most new compounds, which, taken together with the International Prognostic Scoring System, provide a uniform basis for the management of individual patients. The recent introduction of certain new agents, as well as an apparent increase in the use of stem cell transplantation with a variety of so-called reduced-intensity settings, has indeed raised the hope that we are entering a new era of MDS treatment.
Key words Myelodysplastic syndromes Treatment Classification References
Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of the myelodysplastic syndromes.
Br J Haematol
Larson RA. Myelodysplasia: when to treat and how.
Best Pract Res Clin Haematol
Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment.
Mayo Clin Proc
Lindberg EH. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
Curr Drug Targets
Schiffer CA. Clinical issues in the management of patients with myelodysplasia.
Hematology Am Soc Hematol Educ Program 2006:205-210.
Hamblin TJ. Epidemiology of the myelodysplastic syndromes. In: Bennett JM, ed.
The Myelodysplastic Syndromes: Pathobiology and Clinical Management New York, NY: Marcel Dekker; 2002:15–27.
Aul C, Germing U, Gatterman N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious?
Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes.
Int J Hematol
Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AO. Myelodysplastic syndromes: the complexity of stem-cell diseases.
Nat Rev Cancer
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes.
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.
Cazzola M. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Int J Hematol
Jädersten M, Montgomery SM, Dybedal I, Porwit-McDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
Molldrem JJ, Caples M, Marvoudis D,Plante M, Young NS,Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome.
Br J Haematol
Joná sova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.
Br J Haematol
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
N Engl J Med
Martino P, Lacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
de Witte T, van Biezen A, Brand R, et al. Which myelodysplastic syndrome patients are candidates for transplantation?
Leuk Res. 2006;30(Suppl 1):S21.
Pellagatti A, Fidler C, Wainscoat JS, Boultwood J. Gene expression profiling in the myelodysplastic syndromes.
Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J
Natl Compr Canc Netw
PubMed Copyright information
© The Japanese Society of Hematology 2007